started · updated
Medical researchers identify new indicators for cancer treatment efficacy
A collaborative study between Korea University Guro Hospital and the University of Auckland has identified potential indicators to predict the effectiveness of immunotherapy in patients with stage II to III non-small cell lung cancer. By analyzing PET/CT scans and immune cell characteristics, researchers found that the reduction in the tumor-to-liver uptake ratio (TLR) could help determine the likelihood of complete remission before surgery.
The study observed that patients achieving complete remission showed an 82 percent reduction in TLR, compared to 58 percent in those with incomplete remission. Additionally, higher levels of CD4 T cells and TIGIT-expressing T cells in tumor tissue were linked to better treatment responses.
Separately, research from the Catholic University of Korea involving 3,307 patients with bone-metastatic prostate cancer indicates that long-term use of the bone protection drug denosumab for more than 13 months significantly increases the risk of osteonecrosis of the jaw. The study, published in JAMA Network Open, found the cumulative incidence of jaw necrosis was 12.2 percent for those treated for over 13 months, compared to 3.3 percent for those treated for 7 to 12 months, without providing additional benefits in preventing skeletal complications like fractures.
Entities
Catholic University of Korea · JAMA Network Open · Korea University Guro Hospital · University of Auckland